New Approaches, New Hope
Learn More About OncoSec
IL-12 TAVO
INVESTIGATIONAL INTRATUMORAL
CANCER IMMUNOTHERAPY

“I was headed down a one-way street with a dead end.”

Fran’s Story:
Reclaiming Independence from Melanoma

Watch the video

Learn About OncoSec

CEO LETTER OncoSec CEO, Daniel J. O’Connor, Letter to Shareholders

PARTNERSHIPS  Collaboration with Dana-Farber Cancer Institute

NEW VISCERAL LESION APPLICATOR  OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)

VIDEO  TAVO Demonstration

PRESENTATION  Corporate Presentation

Clinical trials of today may power the medical advances of tomorrow

Learn more about our current clinical trials:

MerckAdvanced Melanoma

Triple Negative Breast Cancer

Spotlight 

PharmaVoice: The Intersection of Physics and biology

INTRATUMORAL DELIVERY – Arming the Immune System; Turning Cold Tumors Hot

Nature Gene Therapy: Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy

News & Events

Sep 6, 2019
OncoSec to Present at the 21st Annual H.C. Wainwright Global Investment Conference
Jul 29, 2019
OncoSec Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Application with Claims Covering Cytokine-Based Intratumoral Immunotherapies
Jul 16, 2019
OncoSec Issues Letter to Shareholders
Jun 27, 2019
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
Jun 17, 2019
OncoSec Announces Research Collaboration with Roswell Park Comprehensive Cancer Center Using Cutting-Edge Intravital Microscopy (IVM), TAVO-PLUS and APOLLO™ Electroporation Generator
Jun 13, 2019
OncoSec to Present Immunological Data at World Pharma Week 2019

Tavokinogene Telseplasmid “TAVO” IL-12

Designed to take the fight directly to the tumor

We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.

Learn More

Designed to Arm the Immune System to Fight Cancer

Clinical Pipeline

Pipeline
Our core technology platform continues to advance through clinical trials for various cancers.

Learn More

Technology

Technology
The Intratumoral IL-12 platform is designed to boost the immune system to recognize and attack tumors.

Learn More

Collaborators

Collaborators
OncoSec continues to establish relationships with industry leaders to further advance our research.

Learn More